Dover has entered into a definitive settlement to accumulate Malema Engineering Corp, a US designer and manufacturer of high-precision, mission-critical flow-measurement and control devices for the biopharmaceutical, semiconductor and industrial sectors.
Image: dizain/Adobe Stock.
Malema’s products will increase Dover’s biopharma single-use manufacturing providing, which already consists of Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with services in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in income during the full yr 2022.
When เพรสเชอร์เกจลม closes, Malema will become a part of the PSG business unit inside Dover’s Pumps & Process Solutions phase.
“We see an incredible long-term progress opportunity within the bioprocessing business driven by a strong and rising pipeline of effective novel biologic drugs, biosimilars, protein therapies, non-COVID mRNA vaccines, in addition to budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the growing adoption of more efficient single-use manufacturing processes helps a robust outlook for our choices of single-use elements to end-customers. We consider that pairing Malema’s know-how with our existing portfolio of single-use pumps for biopharma processing will greatly improve the accuracy and worth proposition of our solutions to our customers.”
“We are methodically building out our biopharma platform through proactive capacity additions, new product growth, and opportunistic acquisitions of highly-attractive niche element technologies,” said Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing technology and additional strengthens our sensor portfolio with new proprietary technology. In addition to attractive biopharma functions, we count on strong progress in the semiconductor house on the capability enlargement and re-shoring tailwinds.”
Share